GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Piotroski F-Score

STRO (Sutro Biopharma) Piotroski F-Score : 2 (As of Mar. 19, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sutro Biopharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Sutro Biopharma's Piotroski F-Score or its related term are showing as below:

STRO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 2

During the past 9 years, the highest Piotroski F-Score of Sutro Biopharma was 5. The lowest was 1. And the median was 3.


Sutro Biopharma Piotroski F-Score Historical Data

The historical data trend for Sutro Biopharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Piotroski F-Score Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 3.00 1.00 5.00 3.00 2.00

Sutro Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 4.00 2.00

Competitive Comparison of Sutro Biopharma's Piotroski F-Score

For the Biotechnology subindustry, Sutro Biopharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -58.213 + -48.018 + -48.787 + -72.443 = $-227.46 Mil.
Cash Flow from Operations was -64.741 + 9.455 + -64.516 + -71.738 = $-191.54 Mil.
Revenue was 13.008 + 25.706 + 8.52 + 14.809 = $62.04 Mil.
Gross Profit was 13.008 + 25.706 + 8.52 + 14.809 = $62.04 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(470.736 + 403.402 + 489.043 + 451.832 + 387.207) / 5 = $440.444 Mil.
Total Assets at the begining of this year (Dec23) was $470.74 Mil.
Long-Term Debt & Capital Lease Obligation was $15.67 Mil.
Total Current Assets was $343.31 Mil.
Total Current Liabilities was $131.89 Mil.
Net Income was -50.05 + -38.524 + -49.284 + 31.065 = $-106.79 Mil.

Revenue was 12.674 + 10.412 + 16.924 + 113.721 = $153.73 Mil.
Gross Profit was 12.674 + 10.412 + 16.924 + 113.721 = $153.73 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(406.944 + 358.016 + 464.899 + 431.734 + 470.736) / 5 = $426.4658 Mil.
Total Assets at the begining of last year (Dec22) was $406.94 Mil.
Long-Term Debt & Capital Lease Obligation was $23.15 Mil.
Total Current Assets was $421.54 Mil.
Total Current Liabilities was $93.75 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sutro Biopharma's current Net Income (TTM) was -227.46. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sutro Biopharma's current Cash Flow from Operations (TTM) was -191.54. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-227.461/470.736
=-0.4832029

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-106.793/406.944
=-0.26242677

Sutro Biopharma's return on assets of this year was -0.4832029. Sutro Biopharma's return on assets of last year was -0.26242677. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sutro Biopharma's current Net Income (TTM) was -227.46. Sutro Biopharma's current Cash Flow from Operations (TTM) was -191.54. ==> -191.54 > -227.46 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=15.674/440.444
=0.03558682

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=23.154/426.4658
=0.05429275

Sutro Biopharma's gearing of this year was 0.03558682. Sutro Biopharma's gearing of last year was 0.05429275. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=343.31/131.893
=2.60294329

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=421.542/93.746
=4.49663986

Sutro Biopharma's current ratio of this year was 2.60294329. Sutro Biopharma's current ratio of last year was 4.49663986. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sutro Biopharma's number of shares in issue this year was 82.513. Sutro Biopharma's number of shares in issue last year was 60.972. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=62.043/62.043
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=153.731/153.731
=1

Sutro Biopharma's gross margin of this year was 1. Sutro Biopharma's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=62.043/470.736
=0.13179999

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=153.731/406.944
=0.37776942

Sutro Biopharma's asset turnover of this year was 0.13179999. Sutro Biopharma's asset turnover of last year was 0.37776942. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sutro Biopharma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Sutro Biopharma  (NAS:STRO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sutro Biopharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Executives
Nicki Vasquez officer: Chief Port. Strat & Alnce Ofcr C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Hans-peter Gerber officer: Chief Scientific Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla officer: Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan officer: Chief Tech Op Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman officer: Chief Medical Officer 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell director, officer: CEO & President 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung officer: Chief Commercial Officer C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam officer: Chief Science Officer PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick officer: Chief People & Comm. Officer NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek director C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121